These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3503120)

  • 1. Effects of eyelid closure and nasolacrimal duct occlusion on the systemic absorption of ocular timolol in human subjects.
    Kaila T; Huupponen R; Salminen L
    J Ocul Pharmacol; 1986; 2(4):365-9. PubMed ID: 3503120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The importance of eyelid closure and nasolacrimal occlusion following the ocular instillation of topical glaucoma medications, and the need for the universal inclusion of one of these techniques in all patient treatments and clinical studies.
    Flach AJ
    Trans Am Ophthalmol Soc; 2008; 106():138-45; discussion 145-8. PubMed ID: 19277229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New technique to reduce systemic side effects of timolol eye drops: The tissue press method-Cross-over clinical trial.
    Müller L; Jensen BP; Bachmann LM; Wong D; Wells AP
    Clin Exp Ophthalmol; 2020 Jan; 48(1):24-30. PubMed ID: 31525271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving the therapeutic index of topically applied ocular drugs.
    Zimmerman TJ; Kooner KS; Kandarakis AS; Ziegler LP
    Arch Ophthalmol; 1984 Apr; 102(4):551-3. PubMed ID: 6704011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of nasolacrimal occlusion on timolol concentrations in the aqueous humor of the human eye.
    Ellis PP; Wu PY; Pfoff DS; Bloedow DC; Riegel MR
    J Pharm Sci; 1992 Mar; 81(3):219-20. PubMed ID: 1640356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic index of pilocarpine, carbachol, and timolol with nasolacrimal occlusion.
    Zimmerman TJ; Sharir M; Nardin GF; Fuqua M
    Am J Ophthalmol; 1992 Jul; 114(1):1-7. PubMed ID: 1621773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic absorption pathways of topically applied beta adrenergic antagonists in the pigmented rabbit.
    Lee YH; Kompella UB; Lee VH
    Exp Eye Res; 1993 Sep; 57(3):341-9. PubMed ID: 7901046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic side effects from ophthalmic timolol and their prevention.
    Fraunfelder FT; Meyer SM
    J Ocul Pharmacol; 1987; 3(2):177-84. PubMed ID: 3503912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nasal and conjunctival contributions to the systemic absorption of topical timolol in the pigmented rabbit: implications in the design of strategies to maximize the ratio of ocular to systemic absorption.
    Chang SC; Lee VH
    J Ocul Pharmacol; 1987; 3(2):159-69. PubMed ID: 3503911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma kinetics and antagonist activity of topical ocular timolol in elderly patients.
    Vuori ML; Kaila T
    Graefes Arch Clin Exp Ophthalmol; 1995 Mar; 233(3):131-4. PubMed ID: 7758979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving the safety of topically applied timolol in the pigmented rabbit through manipulation of formulation composition.
    Podder SK; Moy KC; Lee VH
    Exp Eye Res; 1992 May; 54(5):747-57. PubMed ID: 1623960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic absorption of topically applied ocular timolol.
    Kaila T; Salminen L; Huupponen R
    J Ocul Pharmacol; 1985; 1(1):79-83. PubMed ID: 3880069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative effectiveness of prodrug and viscous solution approaches in maximizing the ratio of ocular to systemic absorption of topically applied timolol.
    Chang SC; Chien DS; Bundgaard H; Lee VH
    Exp Eye Res; 1988 Jan; 46(1):59-69. PubMed ID: 3342834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic bioavailability and cardiopulmonary effects of 0.5% timolol eyedrops.
    Korte JM; Kaila T; Saari KM
    Graefes Arch Clin Exp Ophthalmol; 2002 Jun; 240(6):430-5. PubMed ID: 12107508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duration and long-term efficacy of phenylephrine-induced reduction in the systemic absorption of ophthalmic timolol in rabbits.
    Järvinen K; Urtti A
    J Ocul Pharmacol; 1992; 8(2):91-8. PubMed ID: 1506759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled ocular timolol delivery: systemic absorption and intraocular pressure effects in humans.
    Urtti A; Rouhiainen H; Kaila T; Saano V
    Pharm Res; 1994 Sep; 11(9):1278-82. PubMed ID: 7816756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review: systemic absorption of topically applied ocular drugs in humans.
    Salminen L
    J Ocul Pharmacol; 1990; 6(3):243-9. PubMed ID: 2290070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application site dependent ocular absorption of timolol.
    Urtti A; Sendo T; Pipkin JD; Rork G; Repta AJ
    J Ocul Pharmacol; 1988; 4(4):335-43. PubMed ID: 3246568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocular drug interactions involving topically applied timolol in the pigmented rabbit.
    Luo AM; Sasaki H; Lee VH
    Curr Eye Res; 1991 Mar; 10(3):231-40. PubMed ID: 2044391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of drug release rate on systemic timolol absorption from polymeric ocular inserts in the pigmented rabbit.
    Lee VH; Li SY; Sasaki H; Saettone MF; Chetoni P
    J Ocul Pharmacol; 1994; 10(2):421-9. PubMed ID: 8083561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.